AstraZeneca agreement with Genzyme on Caprelsa

RNS Number : 1204U
AstraZeneca PLC
27 July 2015
 



ASTRAZENECA FURTHER SHARPENS FOCUS THROUGH AGREEMENT WITH GENZYME FOR

RARE DISEASE MEDICINE CAPRELSA

 

 

AstraZeneca today announced that it has entered into a definitive agreement with Genzyme to divest Caprelsa® (vandetanib), a rare disease medicine.

 

Caprelsa was granted Orphan Drug Designation by the US FDA in 2005 and is currently available in 28 countries for the treatment of aggressive and symptomatic medullary thyroid carcinoma, with global product sales of $48 million in 2014.

 

Under the terms of the agreement, Genzyme will pay AstraZeneca up to $300 million, including an upfront payment of $165 million to acquire the global rights to sell and develop Caprelsa, and further development and sales milestone payments of up to $135 million. The transaction does not include the transfer of any AstraZeneca employees or facilities. As an asset divestment, upfront receipt and any subsequent payments will be reported in Other Operating Income in the Company's financial statements.

 

Luke Miels, Executive Vice President, Global Product & Portfolio Strategy and Corporate Affairs, AstraZeneca, said: "Caprelsa is a rare disease therapy and the divestment to Genzyme, an expert leader in endocrinology, demonstrates our commitment to ensure patients continue to have access to this medicine while we sharpen our focus on key disease areas."

Genzyme's President and CEO, David Meeker, MD, said: "The addition of Caprelsa represents a strong strategic fit for our rare endocrinology portfolio and underscores Genzyme's commitment to addressing unmet needs in the thyroid community. We look forward to bringing our rare disease expertise to appropriate patients with advanced stage thyroid carcinoma."

The divestment transaction is subject to closing conditions, including the receipt of antitrust clearance from the US Federal Trade Commission. The transaction is expected to complete in the second half of 2015 and does not impact AstraZeneca's financial guidance for 2015.

 

About Genzyme, a Sanofi Company 

Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme's portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world's largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Learn more at www.genzyme.com. Genzyme® is a registered trademark of Genzyme Corporation. All rights reserved.

 

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

 

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

 

CONTACTS

 

Media Enquiries




Esra Erkal-Paler

UK/Global

+44 20 7604 8030


Vanessa Rhodes

UK/Global

+44 20 7604 8037


Ayesha Bharmal

UK/Global

+44 20 7604 8034


Jacob Lund

Sweden

+46 8 553 260 20


Michele Meixell

US

+ 1 302 885 6351






Investor Enquiries




UK




Thomas Kudsk Larsen


+44 20 7604 8199   

+44 7818 524185

Eugenia Litz

Respiratory, Inflammation and Autoimmunity

+44 20 7604 8233   

+44 7884 735627

Nick Stone

Cardiovascular and Metabolic Disease

+44 17 6326 3994   

+44 7717 618834

Karl Hård

Oncology

+44 20 7604 8123

+44 7789 654364

Craig Marks

Infection, Neuroscience and Gastrointestinal Disease

+44 20 7604 8591  

+44 7881 615764

Christer Gruvris


+44 20 7604 8126

+44 7827 836825

 

US




Dial / Toll-Free


  +1 301 398 3251

+1 866 381 7277

 

 

27 July 2015

-ENDS-


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRUBUVRVSABURR

Companies

AstraZeneca (AZN)
UK 100

Latest directors dealings